Key result
Cardiovascular risk factor management, including control of hypertension, dyslipidemia, and anemia, is essential to reduce the high risk of cardiovascular events in patients with chronic kidney disease.
Why the study?
Cardiovascular disease is the leading cause of morbidity and death in patients with chronic kidney disease, making the management of cardiovascular risk in this population a significant clinical challenge.
This review emphasizes the critical importance of screening and managing cardiovascular risk factors such as hypertension and dyslipidemia to reduce morbidity and mortality in patients with chronic kidney disease.
More than 700 million individuals are thought to have chronic kidney disease (CKD) globally, and the incidence is continuing to rise as a result of an aging population and the spread of chronic illnesses like diabetes and hypertension. The most common cause of morbidity and death in nephropathy patients is cardiovascular disease. In clinical practice, managing nephropathy and cardiovascular risk in nephropathic patients is a significant problem. Each patient needs a thorough examination and specialized treatment. To lower the risk of cardiovascular events in nephropathy patients, cardiovascular risk factors must be prevented and promptly treated. To increase the quality of life and survival of nephropathic patients, it is crucial to recognize and treat cardiovascular problems.
No takes yet. Share an insight, caveat, or question.
Álvarez et al. (2023) conducted a review in Chronic kidney disease. Cardiovascular risk factor management was evaluated. Cardiovascular risk factor management, including control of hypertension, dyslipidemia, and anemia, is essential to reduce the high risk of cardiovascular events in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: